SCHEMBL17260396

SCHEMBL17260396

Fc1cc(OCCCN2CCOCC2)ccc1Br

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 6/20 0.59
ALDH1A1 P00352 3/20 0.59
MAPK1 P28482 2/20 0.59
SIGMAR1 Q99720 2/20 0.59
CYP1A2 P05177 1/20 0.59
CHRM2 P08172 1/20 0.59
CHRM1 P11229 1/20 0.59
HTR2A P28223 1/20 0.59
SCN1A P35498 1/20 0.59
HTR2B P41595 1/20 0.59
KCNH2 Q12809 1/20 0.59
SCN2A Q99250 1/20 0.59
SCN3A Q9NY46 1/20 0.59
USP2 O75604 1/20 0.58
LMNA P02545 1/20 0.58
KDM4E B2RXH2 5/20 0.56
TSHR P16473 1/20 0.56
HRH2 P25021 1/20 0.52
HRH1 P35367 1/20 0.52
HTT P42858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL538618 0.93 ALDH1A1 (0.60) HRH3ALDH1A1MAPK1SIGMAR1CYP1A2
SCHEMBL3573539 0.86 HRH3 (0.59) HRH3ALDH1A1KCNH2LMNAKDM4E
SCHEMBL18763475 0.84 HRH3 (0.59) HRH3ALDH1A1MAPK1SIGMAR1CYP1A2
SCHEMBL28826913 0.84 HRH3 (0.53) HRH3ALDH1A1HRH2HRH1SMN1; SMN2
SCHEMBL15301024 0.80 TSHR (0.83) HRH3ALDH1A1MAPK1SIGMAR1CYP1A2
SCHEMBL13033230 0.79 MAPK1 (0.65) ALDH1A1MAPK1USP2KDM4ETSHR
SCHEMBL21636718 0.78 KDM4E (0.65) HRH3ALDH1A1MAPK1SIGMAR1CYP1A2
SCHEMBL1911879 0.78 NPC1 (0.69) HRH3ALDH1A1MAPK1SIGMAR1CYP1A2
SCHEMBL538363 0.78 ALDH1A1 (0.54) HRH3ALDH1A1MAPK1SIGMAR1USP2
SCHEMBL1419662 0.77 ALDH1A1 (0.58) HRH3ALDH1A1MAPK1SIGMAR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3143007-B1 ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2018-07-11 EP disclosed
US-9796686-B2 Antibacterial quinazoline-4(3H)-one derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2017-10-24 US disclosed
US-20170081292-A1 ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2017-03-23 US disclosed
EP-3143007-A1 ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES Actelion Pharmaceuticals Ltd (CH) 2017-03-22 EP disclosed
WO-2015173329-A1 ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081292-A1 ANTIBACTERIAL QUINAZOLINE-4(3H)-ONE DERIVATIVES MRPL21, PYM1, MDK HRH3 105/4885ALDH1A1 942/4885MAPK1 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.